Bevacizumab Biosimilar IBI305 plus sintilimab

DRUG2 trials

Sponsors

Ze-yang Ding, MD, Tongji Hospital

Conditions

Hepatocellular Carcinoma Non-resectable

Unknown Phase

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

RecruitingNCT05713994

Ze-yang Ding, MDHepatocellular Carcinoma Non-resectable

Start: 2020-05-19End: 2025-12-30Target: 300Updated: 2025-03-25

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

RecruitingNCT05717738

Tongji HospitalHepatocellular Carcinoma Non-resectable

Start: 2022-01-20End: 2024-12-31Target: 300Updated: 2024-06-13